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Summary 
 
There is strong research evidence to support the pharmacological treatment of post-
traumatic stress disorder (PTSD) as a second line to trauma-focused psychological 
interventions.  Fluoxetine, paroxetine, sertraline and venlafaxine are the best evidenced 
drugs with lower level evidence for other medications.  It is important that prescribing for 
PTSD is evidence-based. 
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Post-traumatic stress disorder (PTSD) is common and associated with significant distress and 
impaired functioning.  Thankfully, a number of psychological and pharmacological 
treatments have been shown to help.  Trauma-focused psychological interventions in the 
form of cognitive-behavioural therapies with a trauma focus (CBT-TF) and eye movement 
desensitisation and reprocessing (EMDR) are recommended as the treatments of choice for 
PTSD by most guidelines1, including those recently published by the UK’s National Institute 
for Care and Health Excellence (NICE)2 and the International Society for Traumatic Stress 
Studies (ISTSS)3.  Pharmacological approaches are recommended as second line treatments 
but medication is widely prescribed for PTSD and it is important that it is prescribed in an 
evidence-based manner.   
 
Are psychological treatments more effective than pharmacological treatments? 
 
As suggested by guideline recommendations, the magnitude of benefit for pharmacological 
interventions has been found to be inferior to that for trauma-focused psychological 
interventions; small mean effect sizes of less than 0.4 are found for the most effective drugs 
and large mean effect sizes of over 1.2 for CBT-TF and EMDR2,3.  It is, however, notoriously 
difficult to directly compare the results of randomised controlled trials (RCTs) of 
psychological and pharmacological approaches due to important methodological 
differences.   
 
In contrast to the pharmacological placebo, it is very difficult to design and provide a 
convincing psychological placebo and virtually impossible to blind providers and recipients 
to what psychological intervention is being given and received.  The meta-analyses that 
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underpin PTSD guideline recommendations for psychological treatments use data from RCTs 
with a waiting list or usual care control.  The meta-analyses for pharmacological treatments 
use data from RCTs with a placebo control.  Demonstrating efficacy against a placebo is 
more difficult to achieve than against a waiting-list control and, therefore, the apparent 
magnitude of superiority of psychological over pharmacological treatments for PTSD is likely 
to be overestimated by considering raw effect size estimates alone. 
 
The ISTSS prevention and treatment guidelines for PTSD took the likely influence of different 
control conditions into account by setting a lower effect size threshold for the strong 
recommendation of treatments evaluated through placebo-controlled RCTs than those 
evaluated through waiting-list/usual care controlled RCTs3.  The correct level at which to set 
such thresholds is, however, unknown and open to debate.  The ISTSS effect size thresholds 
were 0.4 for placebo-controlled trials and 0.8 for those with waiting-list/usual care controls; 
these were set by a committee of experts and, therefore, need to be interpreted with a 
degree of caution.   
 
A strong placebo effect has been found in PTSD treatment trials.  In one of the two RCTs of 
venlafaxine that contribute to the ISTSS and NICE guidelines, participants receiving 
venlafaxine experienced a mean reduction of 64% in their clinician-rated PTSD symptoms 
compared to 54% for those who received placebo.  This resulted in a small mean effect size 
of around 0.3, clearly underestimating the real benefit people with PTSD who took 
venlafaxine experienced, albeit probably accurately representing the proportion of that 
benefit directly attributable to the unique chemical composition of venlafaxine.  How to 
capture the placebo effect without prescribing a placebo remains a challenging conundrum 
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faced in many areas of health care.  There is some evidence that the placebo effect is 
stronger in the acute phase of treatment and tends to wane, with true medication effects 
lasting longer, so RCTs of longer duration could better tease out the difference. 
 
What do PTSD treatment guidelines recommend? 
 
The current NICE guidelines recommend selective serotonin reuptake inhibitors as a group 
and venlafaxine as the first line pharmacological treatments for PTSD.  The ISTSS guidelines, 
like the original NICE guidelines, considered individual drugs separately and found 
fluoxetine, paroxetine and sertraline to be the only SSRIs with definite efficacy and, 
therefore, recommend these three by name, alongside venlafaxine, as the pharmacological 
treatments of choice for PTSD.  
 
Both the NICE and ISTSS guidelines recommend antipsychotic medications as second line 
pharmacological approaches. NICE does not differentiate between antipsychotics; ISTSS 
recommends quetiapine alone as it was the only antipsychotic found to have any evidence 
of efficacy as a monotherapy and this was limited to one RCT with a total of 80 participants.  
Ultimately, the differences in recommendations between these and the other major PTSD 
treatment guidelines are minor and they provide a clear and relatively consistent 
prescribing message1. 
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Implementing PTSD treatment guideline recommendations in practice 
 
It seems highly likely that more people with PTSD would benefit from medication if it were 
prescribed according to the current evidence base.  Guidelines should facilitate this but, 
sadly, rarely provide sufficient detail to allow clinicians to determine the optimal way to 
prescribe recommended drugs.  This probably contributes to their lack of widespread 
implementation and to sub-optimal prescribing.  To address this gap, we developed the 
Cardiff PTSD Prescribing Algorithm (downloadable from BJPsych Supp materials) to help 
clinicians make appropriate decisions about the pharmacological treatment for people with 
PTSD, primarily based on the ISTSS evidence-based recommendations.  The algorithm is 
designed for PTSD as opposed to Complex PTSD (CPTSD) but, given the absence of evidence 
with respect to the pharmacological treatment of CPTSD specifically, and the overlap 
between PTSD and CPTSD, it also represents an evidence-informed approach to the 
pharmacological treatment of CPTSD.   
 
In order to determine appropriate guidance for the algorithm, we considered the dosing 
regimens used in all the RCTs included in the meta-analyses that led to the ISTSS and NICE 
recommendations. Interestingly, the mean doses of all the recommended drugs used 
approached the maximum dose determined in the British National Formulary4.  This 
suggests that a significant number of people with PTSD will only benefit optimally from 
recommended pharmacological treatments if they take higher doses of them.   
 
As part of the development of the ISTSS guidelines, a systematic review of augmentation of 
pharmacological therapy with other pharmacological agents was undertaken.  This revealed 
 8 
evidence that prazosin, an alpha-1 adrenoceptor antagonist, and risperidone can improve 
PTSD symptoms when added to another medication (usually a SSRI or a SNRI).  This allowed 
us to include evidence-based guidance on what to do if a person with PTSD does not fully 
respond to monotherapy.  We were also able to include drugs with lower levels of RCT 
evidence (e.g. from one small RCT alone) as possible later pharmacological options and 
provide guidance on the management of specific problematic symptoms that often present 
with PTSD but may need addressing separately (e.g. marked agitation and insomnia).   
 
The algorithm encourages a measurement-based approach to care, not least given the 
evidence that this is a more reliable way to prescribe antidepressants than relying on 
clinician judgement alone5.  After assessment and a fully-informed decision by the person 
with PTSD to receive medication, it is recommended that fluoxetine, paroxetine or sertraline 
is tried with escalation of dose at monthly intervals depending on response and tolerability.  
Venlafaxine is advocated as second line with either prazosin or quetiapine (preferred to 
risperidone on account of side-effect profile) augmentation the third line.  If a person with 
PTSD either does not want or is unable to tolerate an antidepressant then it would be 
reasonable to use prazosin or quetiapine as monotherapy. The final step is to consider drugs 
from other classes with less evidence of effect (e.g. amitriptyline or phenelzine).  In addition 
to these suggested steps, the algorithm provides information on side-effect profiles, 
monitoring requirements and specific issues around the initiation and dose escalation of 
prazosin.  
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Conclusion 
 
At present, four medications (fluoxetine, paroxetine, sertraline and venlafaxine) have robust 
evidence of low effect for people with PTSD, making them an important treatment option 
and one that it is important for clinicians who see people with PTSD to be familiar with.  A 
number of other evidence-based pharmacological options also exist.  Despite trauma-
focused psychological interventions being the first-line treatment, most people with PTSD 
who present for help will be prescribed psychotropic medication and there are a number of 
reasons why pharmacological treatment should be considered.  These include: evidence for 
effect; personal choice; waiting lists for psychological treatment; factors including lack of 
stability that prevent psychological treatment; presence of comorbidity/specific symptom 
profiles; and ongoing symptoms despite psychological treatment.   
 
More work is needed to develop more effective pharmacological treatments for PTSD but a 
systematic and measurement-based approach to prescribing, based on the current 
evidence, would be likely to reduce the burden of PTSD and lead to improved health and 
wellbeing for people with this condition. 
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